Palisade Bio, Inc. (PALI)Healthcare | Biotechnology | Denver, United States | NasdaqCM
2.40 USD
+0.07
(3.004%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.38 -0.02 (-0.019%) ⇩ (April 17, 2026, 7:54 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 6:06 p.m. EDT
PALI represents a high-volatility, binary event play driven by speculative analyst optimism and recent positive Phase 1b data, rather than fundamental profitability. While the stock is currently exhibiting strong upward momentum with a significant 30%+ rally off its 50-day average, the negative earnings trajectory, cash burn, and recent equity dilution ($3M raise) create a classic speculative biotech setup. The forecasting model indicates a mild bullish bias (approx. 6.7%) but is heavily compromised by extreme serial correlation (Ljung-Box p-value near zero), suggesting the current price action is trending mechanically rather than efficiently, making this a precarious short-term momentum trade with significant downside risk if clinical data fails to meet inflated expectations. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.072338 |
| MSTL | 0.073144 |
| AutoTheta | 0.073373 |
| AutoARIMA | 0.088125 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.372 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.055 |
| Market Cap | 402,292,096 |
| Forward P/E | -8.57 |
| Beta | 1.47 |
| Previous Name | Seneca Biopharma, Inc. |
| Website | https://www.palisadebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.3802817 |
| Address1 | 4,600 South Syracuse Street |
| Address2 | Suite 900 |
| All Time High | 5,627,700.0 |
| All Time Low | 0.53 |
| Ask | 2.41 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 3,580,900 |
| Average Daily Volume3 Month | 3,956,788 |
| Average Volume | 3,956,788 |
| Average Volume10Days | 3,580,900 |
| Beta | 1.47 |
| Bid | 1.75 |
| Bid Size | 2 |
| Book Value | 0.811 |
| City | Denver |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.4 |
| Current Ratio | 28.952 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.45 |
| Day Low | 2.275 |
| Debt To Equity | 0.055 |
| Display Name | Palisade Bio |
| Dividend Date | 1,563,408,000 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -18,053,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.669 |
| Enterprise Value | 264,811,568 |
| Eps Current Year | -0.192 |
| Eps Forward | -0.28 |
| Eps Trailing Twelve Months | -0.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8622 |
| Fifty Day Average Change | 0.5378001 |
| Fifty Day Average Change Percent | 0.28879824 |
| Fifty Two Week Change Percent | 238.02817 |
| Fifty Two Week High | 2.64 |
| Fifty Two Week High Change | -0.24000001 |
| Fifty Two Week High Change Percent | -0.09090909 |
| Fifty Two Week Low | 0.53 |
| Fifty Two Week Low Change | 1.8700001 |
| Fifty Two Week Low Change Percent | 3.5283022 |
| Fifty Two Week Range | 0.53 - 2.64 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,175,261,400,000 |
| Float Shares | 122,671,822 |
| Forward Eps | -0.28 |
| Forward P E | -8.571429 |
| Free Cashflow | -5,923,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00028 |
| Held Percent Institutions | 0.81703 |
| Implied Shares Outstanding | 167,621,702 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,534,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado. |
| Long Name | Palisade Bio, Inc. |
| Market | us_market |
| Market Cap | 402,292,096 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_244367385 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -16,781,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 402,292,084 |
| Number Of Analyst Opinions | 8 |
| Open | 2.35 |
| Operating Cashflow | -10,847,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 704 4900 |
| Post Market Change | -0.01910019 |
| Post Market Change Percent | -0.79584116 |
| Post Market Price | 2.3809 |
| Post Market Time | 1,776,470,052 |
| Prev Name | Seneca Biopharma, Inc. |
| Previous Close | 2.33 |
| Price Eps Current Year | -12.5 |
| Price Hint | 4 |
| Price To Book | 2.9593096 |
| Profit Margins | 0.0 |
| Quick Ratio | 28.829 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.0700002 |
| Regular Market Change Percent | 3.0043 |
| Regular Market Day High | 2.45 |
| Regular Market Day Low | 2.275 |
| Regular Market Day Range | 2.275 - 2.45 |
| Regular Market Open | 2.35 |
| Regular Market Previous Close | 2.33 |
| Regular Market Price | 2.4 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 3,533,940 |
| Return On Assets | -0.15542 |
| Return On Equity | -0.24520999 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 167,421,702 |
| Shares Percent Shares Out | 0.1537 |
| Shares Short | 25,770,313 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 26,733,844 |
| Short Name | Palisade Bio, Inc. |
| Short Percent Of Float | 0.1539 |
| Short Ratio | 6.5 |
| Source Interval | 15 |
| State | CO |
| Symbol | PALI |
| Target High Price | 25.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 11.125 |
| Target Median Price | 7.5 |
| Total Cash | 133,385,000 |
| Total Cash Per Share | 0.804 |
| Total Debt | 71,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.53815 |
| Two Hundred Day Average Change | 0.86185014 |
| Two Hundred Day Average Change Percent | 0.5603161 |
| Type Disp | Equity |
| Volume | 3,533,940 |
| Website | https://www.palisadebio.com |
| Zip | 80,237 |